title: Nanodiamond therapeutic delivery agents mediate enhanced chemoresistant tumor treatment.
abstract: Enhancing chemotherapeutic efficiency through improved drug delivery would facilitate treatment of chemoresistant cancers, such as recurrent mammary tumors and liver cancer. One way to improve drug delivery is through the use of nanodiamond (ND) therapies, which are both scalable and biocompatible. Here, we examined the efficacy of an ND-conjugated chemotherapeutic in mouse models of liver and mammary cancer. A complex (NDX) of ND and doxorubicin (Dox) overcame drug efflux and significantly increased apoptosis and tumor growth inhibition beyond conventional Dox treatment in both murine liver tumor and mammary carcinoma models. Unmodified Dox treatment represents the clinical standard for most cancer treatment regimens, and NDX had significantly decreased toxicity in vivo compared to standard Dox treatment. Thus, ND-conjugated chemotherapy represents a promising, biocompatible strategy for overcoming chemoresistance and enhancing chemotherapy efficacy and safety.
authors.affiliation: George Williams Hooper Foundation, University of California, San Francisco, CA 94143, USA.
authors.forename: Edward K
authors.initials: EK
authors.lastname: Chow
authors.forename: Xue-Qing
authors.initials: XQ
authors.lastname: Zhang
authors.forename: Mark
authors.initials: M
authors.lastname: Chen
authors.forename: Robert
authors.initials: R
authors.lastname: Lam
authors.forename: Erik
authors.initials: E
authors.lastname: Robinson
authors.forename: Houjin
authors.initials: H
authors.lastname: Huang
authors.forename: Daniel
authors.initials: D
authors.lastname: Schaffer
authors.forename: Eiji
authors.initials: E
authors.lastname: Osawa
authors.forename: Andrei
authors.initials: A
authors.lastname: Goga
authors.forename: Dean
authors.initials: D
authors.lastname: Ho
mesh_terms: D018528:ATP-Binding Cassette Transporters / Q000378:metabolism; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D018130:Diamond; D004317:Doxorubicin / Q000008:administration & dosage / Q000493:pharmacokinetics; D004337:Drug Carriers; D016503:Drug Delivery Systems; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D008114:Liver Neoplasms, Experimental / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D050997:Nanomedicine; D049329:Nanostructures; D036103:Nanotechnology; D009374:Neoplasms, Experimental / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology
chemical_list: D018528:ATP-Binding Cassette Transporters; D000970:Antineoplastic Agents; D004337:Drug Carriers; D018130:Diamond; D004317:Doxorubicin